Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial
CNS Drugs · 2025
DOI: 10.1007/s40263-025-01183-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, 2025. Verfasst von Karin Due Bruun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pain Research Group, Pain Center, Odense University Hospital, Heden 9, 5000, Odense C, Denmark. karin.due.bruun@rsyd.dk. Hauptthemen laut MEDLINE: Fibromyalgia, Naltrexone, Narcotic Antagonists, Pain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gigtforeningen, Aase og Ejnar Danielsens Fond, Odense Universitetshospital.
Abstract (Originalsprache)
BACKGROUND: The widespread pain and muscular fatigue characteristics of fibromyalgia are believed to be mediated by central mechanisms. Low-dose naltrexone (LDN) has emerged as a new treatment option for fibromyalgia, possibly modulating central mechanisms via glial or opioid receptors. METHODS: In the randomized, placebo-controlled FINAL trial, 99 women with fibromyalgia were treated with LDN or placebo for 12 weeks. In this secondary analysis, we examined the potential effects of LDN versus placebo on changes from baseline in pain tolerance, temporal summation of pain, and conditioned pain modulation (CPM) in the complete case population (45 versus 47 participants). Measures of muscular fatigue were evaluated using the 30-s chair stand test and a shoulder abduction test. RESULTS: Of the five examined outcomes, only change in CPM showed a significant between-group difference with greater enhancement following LDN treatment (2.0 kPa; 95% confidence interval (CI) 0.4-3.7 kPa) compared with placebo. Within-group changes in CPM showed an increase of 1.2 kPa (95% CI 0.05-2.4 kPa) in the LDN group and a possible decrease of 0.8 kPa (95% CI - 1.9 to 0.4 kPa) in the placebo group. CONCLUSIONS: We found a significant between-group difference in CPM change in favor of LDN. However, this difference was partly explained by a decrease in CPM in the placebo group. Sensitivity analyses showed no association between changes in CPM and clinical pain improvement, suggesting that the group-difference in CPM is a random finding. STUDY REGISTRATION: ClinicalTrials.gov (NCT0427877; registered on 30 January 2020).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pain Research Group, Pain Center, Odense University Hospital, Heden 9, 5000, Odense C, Denmark. karin.due.bruun@rsyd.dk.
- Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. karin.due.bruun@rsyd.dk.
- The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark. karin.due.bruun@rsyd.dk.
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
- The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Rheumatology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
ORCID-Profile: Karin Due Bruun, Robin Christensen, Kirstine Amris, Morten Rune Blichfeldt-Eckhardt, Marius Henriksen, Tine Alkjaer, Palle Toft, Anders Holsgaard-Larsen, Henrik Bjarke Vaegter
Förderung
- Gigtforeningen
- Aase og Ejnar Danielsens Fond
- Odense Universitetshospital
- Odense University Hospital
Zitieren
APA
Bruun, K. D., Christensen, R., Amris, K., Blichfeldt-Eckhardt, M. R., Bye-Møller, L., Henriksen, M., Alkjaer, T., Toft, P., Holsgaard-Larsen, A., & Vaegter, H. B. (2025). Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial. CNS Drugs. https://doi.org/10.1007/s40263-025-01183-7
Vancouver
Bruun KD, Christensen R, Amris K, Blichfeldt-Eckhardt MR, Bye-Møller L, Henriksen M, et al. Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial. CNS Drugs. 2025. doi:10.1007/s40263-025-01183-7
BibTeX
@article{Bruun2025,
author = {Bruun, Karin Due and Christensen, Robin and Amris, Kirstine and Blichfeldt-Eckhardt, Morten Rune and Bye-Møller, Lars and Henriksen, Marius and Alkjaer, Tine and Toft, Palle and Holsgaard-Larsen, Anders and Vaegter, Henrik Bjarke},
title = {Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial},
journal = {CNS Drugs},
year = {2025},
doi = {10.1007/s40263-025-01183-7}
}
EUVIMED